SCHEMBL23819151

SCHEMBL23819151

C[C@H](NC(=O)OC(C)(C)C)C(=O)OCC(C)(C)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
CYP2D6 P10635 1/20 0.43
KMT2A Q03164 1/20 0.42
CTSK P43235 8/20 0.41
CTSS P25774 4/20 0.41
CA12 O43570 1/20 0.41
CA14 Q9ULX7 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
EPHX2 P34913 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20854166 0.88 CA1 (0.49) CA1CA2CA7CYP2D6KMT2A
SCHEMBL20854165 0.88 CA1 (0.49) CA1CA2CA7CYP2D6KMT2A
SCHEMBL28197702 0.85 CA1 (0.46) CA1CA2CA7CYP2D6KMT2A
SCHEMBL23075803 0.85 CA1 (0.46) CA1CA2CA7CYP2D6KMT2A
SCHEMBL19236548 0.85 CA1 (0.46) CA1CA2CA7CYP2D6KMT2A
SCHEMBL23844012 0.83 CA1 (0.45) CA1CA2CA7CYP2D6KMT2A
SCHEMBL28854830 0.83 CA1 (0.45) CA1CA2CA7CYP2D6KMT2A
SCHEMBL23844023 0.83 CA1 (0.45) CA1CA2CA7CYP2D6KMT2A
SCHEMBL14357345 0.82 CYP1A2 (0.54) CA1CA2CA7CYP2D6KMT2A
SCHEMBL15663302 0.82 CYP1A2 (0.54) CA1CA2CA7CYP2D6KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4107164-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 EP disclosed
US-12264173-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2025-04-01 US disclosed
US-20240174704-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2024-05-30 US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 US disclosed
US-11767337-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2023-09-26 US disclosed
EP-4107164-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 EP disclosed
US-20210284670-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284670-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885CA7 4823/4885
US-12264173-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885CA7 4823/4885
US-11767337-B2 Antiviral compounds MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885CA7 4823/4885
US-20240174704-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 CA1 4866/4885CA2 4718/4885CA7 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.